Litcius/Paper detail

A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer

Martin Reck, Alexander Luft, Igor Bondarenko, Serhii Shevnia, Dmytro Trukhin, Н. В. Коваленко, K Vacharadze, Fülöp Andrea, A. Hontsa, Ji Hye Choi, Donghoon Shin

2020Lung Cancer25 citationsDOIOpen Access PDF

Topics & Concepts

MedicineBevacizumabBiosimilarPharmacokineticsImmunogenicityOncologyInternal medicineDouble blindPhases of clinical researchClinical trialChemotherapyAntibodyPathologyImmunologyAlternative medicinePlaceboBiosimilars and Bioanalytical MethodsCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies
A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer | Litcius